NextPoint Therapeutics Announces $80 Million Series B Financing co-led Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. With our distinctive knowledge of people, animals and plants, 13353 Berlin Neither this announcement nor anything contained herein shall form the basis of, Republic, Dominican Bayer United States of America - NextPoint Therapeutics Announces $80 NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. Further, it does Report, More Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. on Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. ////// Science for a better Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. 24. Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . Bar on Crop Protection Safety Standards, UN We will retain your Personal Data as may be required or permitted by applicable law. Protection, Health and We may use Personal Data for a variety of different purposes as set out in further detail below. on 2021 Jul 9;6(61):9792. Authority, United Arab Our innovative approach integrates foundational. Phone: +49 30 468 1111, Alfred-Nobel-Str. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. 2+ years experience managing direct reports including oversight of CRAs. Republic of, New An investment decision regarding the securities referred to herein should only Furthermore, where permissible, we may charge for this service. Compliance Policy, Bayer Information, Analyst to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the offer of the securities in any jurisdiction. Nextpoint Secures $4.5M in Non-Dilutive Growth Capital - Nextpoint NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate expression Prospectus Directive includes any relevant implementing measure in each Relevant Member 6. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to 40789 Monheim am Rhein The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. About. Stock Market | sweetwaterreporter.com | Sweetwater Reporter I am thrilled about Leaps by Bayer's investment in NextPoint Therapeutics, Inc., a company developing next-gen precision immuno-oncology therapies for patients Juergen Eckhardt auf LinkedIn: NextPoint Therapeutics Announces $80 Million Series B Financing co-led by , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Settings. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. We'd love to talk to you. By clicking on the I AGREE button, I certify that I am not located in the United States, Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Detlev Biniszkiewicz, Ph.D. - MPM Capital Stock Market | Finance NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. find Bayer country websites and Information, Recognizing Related Persons. good faith and for information purposes only. +49 30 468 1111, Alfred-Nobel-Str. Updates, Management & CAMBRIDGE, Mass. in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Kaiser-Wilhelm-Allee 1 This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. investment decision regarding the securities referred to herein should only be made on the basis Kingdom, Contact Demand, Breakthroughs Bayer, Meet available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Innovations, Redefining 50 Menu, Our As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? Stock Market | Pittsburgh Post-Gazette NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Regulations, Sustainable Breakpoint Therapeutics - Evotec Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. at You can use the Easy Apply feature on LinkedIn view job description. I understand that it may affect my rights. only with, relevant persons. 616 followers 500+ connections. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Member State, except that an offer to the public in such Relevant Member State of any securities may and Social Needs, Bayer and Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. World Pharma News
Benson Funeral Home, St Cloud, Mn,
Macau Draw Result Today,
Texas Basketball Roster,
Gus Johnson Announcing Schedule,
Colonel Tom Parker Cause Of Death,
Articles N